During the last session, Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s traded shares were 3.06 million, with the beta value of the company hitting 1.93. At the end of the trading day, the stock’s price was $4.73, reflecting an intraday gain of 0.85% or $0.04. The 52-week high for the BCRX share is $9.06, that puts it down -91.54 from that peak though still a striking 1.06% gain since the share price plummeted to a 52-week low of $4.68. The company’s market capitalization is $975.09M, and the average intraday trading volume over the past 10 days was 3.32 million shares, and the average trade volume was 3.39 million shares over the past three months.
Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) trade information
Biocryst Pharmaceuticals Inc. (BCRX) registered a 0.85% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.85% in intraday trading to $4.73, hitting a weekly high. The stock’s 5-day price performance is -5.59%, and it has moved by -14.16% in 30 days. Based on these gigs, the overall price performance for the year is -43.29%. The short interest in Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) is 30.55 million shares and it means that shorts have 9.31 day(s) to cover.
Biocryst Pharmaceuticals Inc. (BCRX) estimates and forecasts
Statistics show that Biocryst Pharmaceuticals Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Biocryst Pharmaceuticals Inc. (BCRX) shares have gone down -30.13% during the last six months, with a year-to-date growth rate more than the industry average at 38.00% against 8.20. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 25.00% this quarter and then jump 60.00% in the quarter after that. In the rating firms’ projections, revenue will increase 19.40% compared to the previous financial year.
Revenue for the current quarter is expected to be $86.29 million as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to $98.6 million by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $68.78 million and $82.49 million respectively. In this case, analysts expect current quarter sales to grow by 25.50% and then jump by 19.50% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -3.73%. While earnings are projected to return 46.44% in 2024, the next five years will return 44.80% per annum.
BCRX Dividends
Biocryst Pharmaceuticals Inc. is due to release its next quarterly earnings between May 01 and May 06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s Major holders
Biocryst Pharmaceuticals Inc. insiders own 1.22% of total outstanding shares while institutional holders control 88.08%, with the float percentage being 89.17%. Blackrock Inc. is the largest shareholder of the company, while 318 institutions own stock in it. As of Jun 29, 2023, the company held over 15.5 million shares (or 8.18% of all shares), a total value of $109.09 million in shares.
The next largest institutional holding, with 15.09 million shares, is of Vanguard Group Inc’s that is approximately 7.96% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $106.23 million.
Also, the Mutual Funds coming in first place with the largest holdings of Biocryst Pharmaceuticals Inc. (BCRX) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Aug 30, 2023 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 8.22 million shares. This amounts to just over 4.34 percent of the company’s overall shares, with a $58.41 million market value. The same data shows that the other fund manager holds slightly less at 5.86 million, or about 3.09% of the stock, which is worth about $41.26 million.
